Facebook Page Lands Drugmaker In Hot Water With FDA

By Jeff Overley (March 12, 2014, 6:08 PM EDT) -- The U.S. Food and Drug Administration on Wednesday published a rare rebuke to a drugmaker over improper promotion on social media, chastising Switzerland-based IBSA Institut Biochimique SA over a Facebook page that allegedly didn't disclose any risks for a drug that has a black box warning.

In its so-called untitled letter, which represents a relatively mild form of discipline, the FDA accused IBSA of creating a Facebook page for hypothyroidism drug Tirosint that failed to mention anything about potential side effects.

A screen grab provided by the FDA doesn't show that any actual posts were made to the page, and displays...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!